IDRA-21 Nootropic Compound Cognitive Enhancer - China Suppliers and Factory - CAS: 22503-72-6, High Purity 98%
Brief Introduction
IDRA-21 is a positive AMPA receptor modulator that inhibits rapid desensitization of AMPA receptors, prolonging the decay time of excitatory postsynaptic currents and enhancing glutamatergic neurotransmission. In recombinant human GluR1/2 flip receptors expressed in HEK 293 cells, IDRA-21 doubled charge transfer at 70 μM concentration.
Oral administration of IDRA-21 significantly improved delayed matching-to-sample task performance in young adult rhesus monkeys. Over the dose range of 0.15–10 mg/kg, improvement was maintained up to 48 hours after single-dose administration. Task accuracy for Long delay trials increased by 34% of vehicle following Best Dose administration.
In aged monkeys (>20 years), IDRA-21 also improved task accuracy, with up to 18% increase for trials associated with Medium delay intervals. No obvious untoward effects were noted in either study group.
During an intermittent dosing schedule over three weeks (dosing every 3 days), IDRA-21 produced a gradual increase in task accuracy maintained above vehicle performance levels, demonstrating that cognitive-enhancing effects can be sustained with repeated administration.
A 2022 study revealed that IDRA-21 not only modulates AMPA receptors but also potentiates kainate receptor-mediated currents. In primary cultures of cerebellar granule neurons, IDRA-21 modulation of kainate receptors primarily involves decreasing receptor desensitization, providing new perspectives for understanding its comprehensive mechanism of action.
In HEK293 cells expressing AMPA receptor subunits, IDRA-21 showed significantly higher efficacy in GluA1 homomeric receptors than in GluA2 homomeric receptors, while potency remained unchanged. This subunit selectivity may provide a basis for designing more selective AMPA receptor modulators.
In cerebellar granule neurons treated with AMPA (50 μM, 1 hour), addition of IDRA-21 (1 mM) induced cytotoxicity, which was blocked by AMPA receptor antagonists GYKI 53655 and NBQX. In a rat global cerebral ischemia model, IDRA-21 (6–24 mg/kg) increased G41 neuronal damage. These findings highlight the importance of dose optimization in research.